Latest news with #Kacholia
Economic Times
14-05-2025
- Business
- Economic Times
Balu Forge Q4 results: Ashish Kacholia portfolio company reports 123% YoY surge in PAT, revenue jumps 63%
Balu Forge Industries on Wednesday reported a 123% year-on-year jump in its Q4FY25 net profit at Rs 63 crore versus Rs 28 crore in the year ago period. The company, which is part of ace investor Ashish Kacholia's stock portfolio, delivered a 67% increase in its revenue from operations at Rs 270 crore versus Rs 161 crore in the corresponding quarter of the previous financial year. ADVERTISEMENT The profit after tax (PAT) rose 6.2% on a sequential basis versus Rs 59 crore in Q3FY25. Meanwhile, the topline was up 5.4% versus Rs 256 crore in the October-December quarter of FY25. Company's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 75 crore versus Rs 34 crore in Q4FY24 witnessing a 118% uptick and Rs 68 crore in Q3FY25, recording an 11% rise. The EBITDA margin for the quarter under review stood at 27.8%, up 647 bps on the YoY basis and 134 bps QoQ basis. For the full financial year the revenue was reported at Rs 924 crore which was up from Rs 560 crore in FY24, witnessing a 65% rise. As for the net profit, a 118% uptick is seen at Rs 204 crore as against Rs 93 crore in the previous financial year. Cash flow from operations stood at Rs 148 crore in FY25, which saw a sharp increase of 566% compared to FY24, underpinned by improved EBITDA and collection of receivables. ADVERTISEMENT Total Debt stood at Rs Rs 36 crore while the cash and equivalents of Rs 96 crore was reported at the end of the financial year, taking the net cash to Rs 60 Debt / Equity reduced to 0.03x as of FY25, down from 0.09x in FY24, reflecting ongoing deleveraging and maintaining its capital structure for future growth initiatives. ADVERTISEMENT Working capital days improved significantly to 104 days in FY25 compared to 129 days in FY24 Return on Capital Employed (ROCE) improved to 30.1%, as a result of higher asset utilization, operational efficiencies and greater value-added product sales. Also Read: Eicher Motors Q4 Results: Cons PAT jumps 27% YoY to Rs 1,362 crore; Rs 70/share dividend declared ADVERTISEMENT Kacholia has 1.66% stake in the company. The multibagger stock is down 22% on the year-to-date basis while its 1-year returns stand at a robust 103%. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Mint
13-05-2025
- Business
- Mint
Ashish Kacholia portfolio stock declares date to announce Q4 results 2025, final dividend for FY25
Ace investor Ashish Kacholia portfolio stock Fineotex Chemical shares gained over 2% on Tuesday despite muted trading volumes. Fineotex Chemical share price gained as much as 2.7% to ₹ 254.90 apiece on the BSE. Fineotex Chemical has announced the date to declare its earnings for the fourth quarter of financial year 2024-2025. The company has announced the date of the meeting of its board of directors to consider and approve the Q4 results as well as earnings for the full financial year 2024-2025. Fineotex Chemical Q4 results will be declared on May 20. Along with Fineotex Chemical Q4 results 2025, the company's board will also consider the recommendation of a final dividend. '...we would like to inform that a meeting of the Board of Directors of the company is scheduled to be held on Tuesday, 20th May, 2025 inter-alia to Consider and approve; 1. The Audited Standalone and Consolidated Financial Statements of the company for the quarter and year ended March 31, 2025; 2. Recommendation of Final Dividend, if any,' Fineotex Chemical said in a regulatory filing on May 12. Meanwhile, the trading window of Fineotex Chemical shares for designated persons will remain closed till 48 hours after the declaration of Q4 results. 'Furtherance to our letter dated March 28, 2025, the Trading Window for dealing in securities of the Company remains closed and will be re-open after completion of 48 hours of declaration of aforesaid financial results,' the company said. Ashish Kacholia holds a significant stake in Fineotex Chemical. As per the shareholding pattern of the company as on March 2025, Ashish Kacholia holds 31,35,568 Fineotex Chemical shares, representing 2.74% stake in the company. Kacholia's shareholding in Fineotex Chemical at the end of March 2025 remained the same as at the end of December 2024. Fineotex Chemical share price has gained 10% over the past month, showing signs of a short-term rebound. However, the small-cap stock remains under pressure on a broader timeline, having declined 27% year-to-date (YTD) and over 30% in the past one year. Despite recent underperformance, Fineotex Chemical share price has delivered stellar long-term returns. Over a five-year period, Fineotex Chemical shares have surged 875%, marking it as a multibagger for long-term investors. At 10:45 AM, Fineotex Chemical share price was trading 2.48% higher at ₹ 254.35 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
02-05-2025
- Business
- Business Standard
Ashish Kacholia portfolio stock surges 10% on strong Q4 performance
Share price of Ami Organics today Share of Ami Organics surged 10 per cent to ₹ 1,243 on the BSE in Friday's intra-day deal, after the company reported healthy operational performance for the quarter ended March 2025 (Q4FY25). In the past two trading days, the stock price of the pharmaceutical company has rallied 14 per cent. It had hit a 52-week high of ₹ 1,321.75 (adjusted to stock split) on February 5, 2025. At 02:31 pm; Ami Organics was trading 6 per cent higher at ₹ 1,196, as compared to 0.15 per cent rise in the BSE Sensex. Stock Split from ₹ 10 to ₹ 5 On April 25, 2025, share price of Ami Organics turned ex-date for stock split. The company had fixed April 25, 2025 as the 'Record Date' for determining entitlement of equity shareholders for the purpose of for split/ sub-division of equity shares of the company, such that 1 equity share having face value of ₹10, divided into 2 equity shares having face value of ₹5 each. The rationale behind the stock split was to enhance liquidity of the equity shares of the company in the stock market and to encourage wider participation of small investors by making equity shares of the company more affordable. Ashish Kacholia holds 1.72 per cent stake in Ami Organics Investor Ashish Kacholia held 704,974 equity shares representing 1.72 per cent stake in Ami Organics at the end of March 2025 quarter, the shareholding pattern data showed. However, Kacholia, reduced his stake in the company by 0.12 percentage points, from 1.84 per cent stake at the end of December 2024 quarter. Q4 operational performance of Ami Organics In January to March 2025 quarter (Q4FY25), Ami Organics reported 144 per cent jump in its consolidated profit after tax (PAT) at ₹ 62.7 crore, against ₹ 25.7 crore in Q4FY24. Revenue from operations grew 37.1 per cent year-on-year (YoY) at ₹ 308.5 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin expanded to 27.5 per cent from 19.2 per cent in Q4FY24. Looking ahead to FY26, the management anticipates robust growth across all business segments, driving confidence in achieving 25 per cent revenue growth. About Ami Organics Ami Organics is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates) for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals including parabens and paraben formulations, methyl salicylate , semiconductor chemicals, electrolyte additives and niche key starting materials (KSM) for cosmetics, fine chemicals and agrochemical industries. The Pharma Intermediates, find application in certain high-growth therapeutic areas including anti-depressant, anti-cancer, anti-retroviral, anti-Parkinson, and seizure disorder. Ami Organics is the market leader for various key intermediates across the globe and the first company in India outside of China to spearhead the pioneering development of electrolyte additives on a global scale.
